Table 1.
Characteristics of Baptist Memorial Healthcare Corporation NSCLC Tumor Registry Cohort
| Demographics | Tumor Registry Cohort | eMTOC | Metropolitana | Regionalb |
|---|---|---|---|---|
| N (%) | 6259 | 864 (14) | 3464 (55) | 1931 (31) |
| Racec | ||||
| White | 4503 (71.9) | 564 (65.3) | 2446 (70.6) | 1493 (77.3) |
| Black or African American | 1688 (27) | 291 (33.7) | 966 (27.9) | 431 (22.3) |
| Other/unknown | 68 (1.1) | 9 (1) | 52 (1.5) | 7 (0.4) |
| Sexc | ||||
| Female | 2857 (45.7) | 435 (50.3) | 1613 (46.6) | 809 (41.9) |
| Male | 3400 (54.3) | 429 (49.7) | 1849 (53.4) | 1122 (58.1) |
| Age in y, median (IQR) | 68 (61–75) | 68 (61–75) | 68 (61–75) | 69 (61–76) |
| Insurancec | ||||
| Medicare | 1444 (23.1) | 197 (22.8) | 872 (25.2) | 375 (19.4) |
| Medicaid | 953 (15.2) | 119 (13.8) | 445 (12.8) | 389 (20.1) |
| Commercial | 3157 (50.4) | 454 (52.5) | 1726 (49.8) | 977 (50.6) |
| Uninsured | 705 (11.3) | 94 (10.9) | 421 (12.2) | 190 (9.8) |
| Clinical stage groupingc,d | ||||
| Early: I/II/IIIA(T3/N1) | 1741 (27.8) | 352 (40.7) | 823 (23.8) | 566 (29.3) |
| Locally-advanced: IIIA(T4/N2)/IIIB | 1128 (18) | 189 (21.9) | 540 (15.6) | 399 (20.7) |
| Advanced: IV | 2745 (43.9) | 246 (28.5) | 1606 (46.4) | 893 (46.2) |
| Unknown | 645 (10.3) | 77 (8.9) | 495 (14.3) | 73 (3.8) |
| Patient ruralityc | ||||
| Not rural | 3760 (60.1) | 693 (80.2) | 2687 (77.6) | 380 (19.7) |
| Rural | 2499 (39.9) | 171 (19.8) | 777 (22.4) | 1551 (80.3) |
| Treatment | ||||
| Stage-preferred treatment ratec,e | 3087 (55) | 520 (66.1) | 1675 (56.4) | 892 (48) |
| Guideline-concordant treatment ratec,e,f | 3839 (68.4) | 618 (78.5) | 2051 (69.1) | 1170 (63) |
| No treatment ratec | 1376 (22.0) | 58 (6.7) | 755 (21.8) | 563 (29.2) |
eMTOC, enhanced Multidisciplinary Thoracic Oncology Conference; IQR, interquartile range.
Metropolitan: patients without care planning through the eMTOC, who received care within metropolitan Memphis.
Regional: patients without care planning through the eMTOC, who received care within institutions outside greater metropolitan Memphis.
Indicates statistically significant differences across the three cohorts (all p < 0.05).
Grouped according to guideline-concordant treatment approach-surgery for early stage, concurrent chemoradiation for locally advanced, palliative systemic therapy for advanced.
According to National Comprehensive Cancer Network guidelines.
Including alternative treatment recommendations acceptable under certain circumstances.